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Various approaches to the synthesis of all four stereoisomers of 2-(1H-imidazol-4-yl)cyclopro-
pylamine (cyclopropylhistamine) are described. The rapid and convenient synthesis and
resolution of trans-cyclopropylhistamine is reported. The absolute configuration of its enanti-
omers was determined by single-crystal X-ray crystallographic analysis. The distinct trans-
cyclopropylhistamine enantiomers were tested for their activity and affinity on the histamine
H3 receptor. (1S,2S)-Cyclopropylhistamine (VUF 5297) acts as an agonist both on the rat cortex
(pD2 ) 7.1; R ) 0.75) and on guinea pig jejunum (pD2 ) 6.6; R ) 0.75). Its enantiomer, (1R,2R)-
cyclopropylhistamine (VUF 5296), is about 1 order of magnitude less active. Both enantiomers
show weak activity on H1 and H2 receptors. All synthetic attempts to cis-cyclopropylhistamine
were unsuccessful. Nevertheless, the results of this study provide an ideal template for
molecular modeling studies of histamine H3 receptor ligands.
Introduction
Next to its role as mediator in (patho)physiological
processes, histamine can be regarded as a neurotrans-
mitter.1 The different pharmacological actions of hista-
mine2 are mediated via the activation of distinct hista-
mine receptor subtypes. In addition to two postsynaptic
receptor subtypes, H1 and H2, a presynaptic H3 receptor
has been identified. The histamine H3 receptor is
responsible for controlling neuronal synthesis of hista-
mine and in addition regulates the release of the
neurotransmitter into the synaptical cleft.3 Further-
more, the receptor has been shown to modulate the
release of other neurotransmitters, e.g., serotonin,4,5
acetylcholine,6 dopamine,7 and noradrenaline,8 in both
the central nervous system (CNS) and the peripheral
nervous system. Therefore the H3 receptor can be
considered a potential target for the development of new
therapeutic agents, e.g., to treat neurologic disorders.9
To determine the precise functional roles of the H3
receptor, it is necessary to develop potent and selective
H3 ligands. Design of such compounds can be facilitated
by molecular modeling. Furthermore, such studies can
help to better understand the molecular mechanisms
involved in receptor stimulation. Therefore, the struc-
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tural features that are responsible for affinity and
intrinsic activity of a ligand need to be resolved.
The development of rigid histamine analogues will
contribute to the determination of the H3 receptor
pharmacophore, as the conformations of these com-
pounds only allow restricted spatial orientation of the
pharmacophoric elements of H3 receptor agonists, i.e.,
the orientation of the imidazole ring with respect to the
basic nitrogen in the side chain of the ligands. A small
and rigid compound such as 2-(1H-imidazol-4-yl)cyclo-
propylamine (cyclopropylhistamine) (1) would be an
ideal template for the development of a pharmacophore
model, using molecular modeling techniques. Some
preliminary pharmacological data for this compound
have been reported in a patent application by Arrang
et al.10 Unfortunately, the stereochemical identity of the
material tested was not reported. Hence, we speculated
that the results reported by Arrang and co-workers
could be based on experiments with racemic mixtures
of both the trans- and cis-diastereoisomers (denoted here
as 1a,b and 1c,d, respectively; Figure 1). As the H3
receptor has proved to be highly stereoselective,11,12 it
is reasonable to assume that each of the stereoisomers
will have a different activity. For molecular modeling
studies, the potencies of each of the distinct isomers has
to be determined. Therefore, we decided to attempt to
synthesize the four stereoisomers of cyclopropylhista-
mine and to study their respective H3 pharmacology.
Chemistry
In the aforementioned patent application by Arrang
et al.10 cyclopropylhistamine (1) was obtained via a route
developed by Burger and co-workers.13 In this route,
cyclopropylhistamine (1) was synthesized starting from
urocanic acid (2), via the cyclopropanation of sec-butyl
trans-3-(1-trityl-1H-imidazol-4-yl)acrylate ((E)-3) with
dimethyloxosulfonium methylide followed by a Curtius
rearrangement of the carboxylate group (Scheme 1). In
our hands, the key step in this synthesis scheme, the
cyclopropanation step, yielded a racemic mixture of
trans-cyclopropane 4a,b in a moderate yield (41%).
No cyclopropane product with the cis-configuration
was detected in the reaction mixture. Efforts to obtain
cis-cyclopropylhistamine (1c,d) via cyclopropanation of
the isomeric sec-butyl cis-3-(1-trityl-1H-imidazol-4-yl)-
acrylate14 ((Z)-3) as starting material also failed. Only
trans-cyclopropanane product 4a,b was obtained. Varia-
tion of the reaction conditions and use of other protective
groups for the imidazole moiety or the carboxylate group
could neither improve the yield nor improve the ster-
eochemical outcome of the reaction. The addition of
sulfonium ylide to the double bond proceeds via a
nonconcerted reaction mechanism, and theoretically the
formation of a mixture of all four cyclopropane stereo-
isomers is possible. However, we have to conclude that
the addition to urocanic acid derivatives exclusively
leads to the thermodynamically most stable product
having the trans-cyclopropane configuration, regardless
of the configuration of the unsaturated bond in the
starting material.
Subsequently, we investigated other methods to ob-
tain this compound in a stereoselective manner. Cyclo-
propanation of the urocanate (E)-5 by the stereospecific
addition of diazomethane, using palladium(II) acetate
as a catalyst, gave the trans-cyclopropane 6a,b in a
moderate yield (Scheme 2). However, it must be noted
that higher temperatures, larger amounts of catalyst,
and repeated applications of the reaction conditions
were required compared to the reported cyclopropana-
tions of analogous non-imidazole R,â-unsaturated car-
boxylic esters.15-17 Alkaline hydrolysis of the ester 6a,b
and subsequent Curtius rearrangement yielded the ra-
cemic trans-cyclopropylhistamine (1a,b). Having ob-
tained only a limited amount of trans-cyclopropylhista-
mine (1a,b) we were unable to separate the enantiomers.
For the synthesis of the cis-isomers of cyclopropyl-
histamine (1c,d), the intermediate cis-urocanate (Z)-5
was prepared by a new synthetic pathway (Scheme 3).
4-Iodo-1H-imidazole (7) protected with an N,N-dimeth-
ylsulfamoyl group was coupled to trimethylsilylacet-
ylene in a palladium-catalyzed reaction.17,18 Removal of
the trimethylsilyl group by treatment with KOH gave
the acetylenic derivative 10 which was treated with
ethylmagnesium bromide and dimethyl carbonate to
provide alkyne ester 11. Subsequent hydrogenation over
Lindlar catalyst19 yielded the cis-urocanate (Z)-5. How-
ever, palladium-catalyzed cyclopropanation of this com-
pound failed. All attempts to perform this reaction
under the same, or even more drastic, conditions
compared to the trans-urocanate (E)-5 did not give the
desired product; only starting material was recovered.
Other metal-catalyzed cyclopropanation procedures
(e.g., Simmons-Smith reactions) on trans-urocanic acid
derivatives such as (E)-5 gave even lower yields of trans-
cyclopropanated product. When using cis-urocanic acid
derivatives such as (Z)-5, these methods failed com-
pletely to give cyclopropanated product. We suggest that
the transition-metal-catalyzed cyclopropanations are
seriously hampered because of chelation of the catalyst
by the imidazole moiety.
We had to conclude that the strategy to synthesize
all isomers of cyclopropylhistamine (1) by cyclopropa-
nation of imidazole-containing precursors suffered from
serious drawbacks. The trans-isomers 1a,b were ob-
tained in a moderate yield, and the limited availability
of the racemic compound hampered efforts to separate
the enantiomers. Furthermore, all attempts to synthe-
size the cis-isomers 1c,d failed.
Therefore, we changed our strategy and developed a
Figure 1. Stereoisomers of cyclopropylhistamine (1).
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new synthesis route, constructing the imidazole ring on
an appropriate cyclopropyl precursor (Scheme 4). Com-
mercially available racemic ethyl trans-2-formyl-1-cy-
clopropanecarboxylate (12a,b) was allowed to react with
(p-tolylsulfonyl)methyl isocyanide (TosMIC) in a [3+2]
anionic cycloaddition.20 The labile 4-tosyloxazoline 13a,b
which precipitated from the reaction mixture was
filtered and immediately treated with a saturated
solution of ammonia in ethanol at 120 °C. Both reaction
steps proceed rapidly and in high yields.
The imidazole nucleus in 14a,b was protected with a
dimethylsulfamoyl group, and the ester 15a,b was
hydrolyzed under basic conditions. Subsequent Curtius
rearrangement gave the isocyanate 16a,b which was
converted directly into the diastereomeric carbamates
17 and 18 using the enantiopure alcohol (R)-(+)-1-(2-
naphthyl)ethanol. The diastereomers were easily sepa-
rated by flash column chromatography. The diastereo-
meric purity of the isolated stereoisomers was verified
by HPLC analysis. The absolute configuration of 18 was
Scheme 1a
a Reagents used: (a) sec-butyl alcohol, H2SO4; (b) Trt-Cl, Et3N, CH2Cl2; (c) Me3SO-I+, NaH, DMF; (d) ì ) 254 nm, CH2Cl2.
Scheme 2a
a Reagents used: (a) HCl(g), MeOH, reflux; (b) dimethylsulfamoyl chloride, Et3N, DCM; (c) CH2N2, cat. Pd(OAc)2, DCM; (d) 1 M KOH,
MeOH, THF; (e) ClCOOEt, Et3N, acetone; (f) NaN3, H2O; (g) toluene, reflux; (h) tert-butyl alcohol, reflux; (i) 1 M HCl, reflux.
Scheme 3a
a Reagents used: (a) dimethylsulfamoyl chloride, Et3N, toluene; (b) trimethylsilylacetylene, cat. (C6H5)3PdCl2, cat. CuI, Et3N, 50 °C;
(c) 2 M KOH, MeOH, THF; (d) EtMgBr, (CH3O)2CO; (e) H2, Lindlar cat., quinoline, acetone; (f) CH2N2, cat. Pd(OAc)2, DCM.
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determined by single-crystal X-ray analysis (Figure 2)
(for details, see the Experimental Section).
Hydrolysis of the distinct diastereoisomers with hy-
drobromic acid gave the enantiopure trans-cyclopropyl-
histamines (1a,b).
In an attempt to prepare cis-cyclopropylhistamine
(1c,d) via an analogous route, racemic ethyl cis-2-
formylcyclopropylcarboxylate21 was reacted with TosMIC.
This resulted in the precipitation of a highly unstable
compound that could not be characterized. Immediate
treatment of this material with ammonia in ethanol
resulted in the formation of tars from which no cyclo-
propylimidazoles could be isolated or identified.
Pharmacological Data
The agonistic activities of the compounds 1a,b on the
histamine H3 receptor were determined on an in vitro
test system based on the electrically evoked contractile
response of isolated guinea pig jejunum segments.22 The
receptor activities were also measured via the release
of [3H]noradrenaline from electrically stimulated rat
cerebral cortex slices.23 Binding affinities were deter-
mined using an H3 receptor binding assay on rat cortex
(for details, see the Experimental Section). The com-
pounds were additionally tested for H2 agonism on the
spontaneously beating guinea pig right atrium24 and
for H1 agonism on guinea pig ileum segments (Table
1).25
Scheme 4a
a Reagents used: (a) tosmic, NaCN, EtOH, 0 °C; (b) EtOH/NH3, 120 °C, 15 bar; (c) Me2NSO2-Cl, Et3N, CH2Cl2; (d) KOH, THF, MeOH;
(e) ClCO2C2H5, Et3N, acetone; (f) NaN3, H2O; (g) toluene, ¢; (h) (R)-(+)-1-(2-naphthyl)ethanol, toluene; (i) 30% HBr, ¢.
Figure 2. ORTEP drawing of 18.
Table 1. Agonistic Activities, Intrinsic Activity (R), and Binding Affinity of the Enantiopure trans-Cyclopropylhistamines
H3 H2 H1
compound configuration pD2a pD2b pKic pD2d pD2e
histamine 7.4 ( 0.1 7.4 ( 0.1 8.2 ( 0.1 6.1 ( 0.1 6.6 ( 0.1
(R ) 1.0) (R ) 1.0) (R ) 1.0) (R ) 1.0)
1a 1R,2R 5.75 ( 0.39 6.15 ( 0.08 7.60 ( 0.1 4.9 ( 0.1 4.5 ( 0.1
(VUF 5296) (R ) 0.64) (R ) 0.32) (R ) 0.9) (R ) 0.9)
1b 1S,2S 7.08 ( 0.15 6.64 ( 0.06 8.76 ( 0.1 4.8 ( 0.1 5.0 ( 0.1
(VUF 5297) (R ) 0.71) (R ) 0.75) (R ) 1.0) (R ) 1.2)
a Functional H3 receptor assay on rat cortex. b Functional H3 receptor assay on guinea pig jejunum. c H3 receptor binding assay on rat
cortex. d Functional H2 receptor assay on guinea pig atrium. e Functional H1 receptor assay on guinea pig jejunum.
1118 Journal of Medicinal Chemistry, 1999, Vol. 42, No. 7 De Esch et al.
Discussion
The histamine H3 receptor affinity of cyclopropylhis-
tamine (1) has been reported in a patent application by
Arrang et al.10 We assume that the material tested by
Arrang and co-workers was a racemic mixture of trans-
cyclopropylhistamine (1a,b). In our efforts to synthesize
all four stereoisomers, we have developed a new route
for the large-scale synthesis and resolution of trans-
cyclopropylhistamine (1a,b). However, all synthetic
attempts to cis-cyclopropylhistamine (1c,d) were unsuc-
cessful.
Pharmacological evaluation of the enantiopure prod-
ucts 1a,b confirmed once more the stereoselectivity of
the H3 receptor. We established (1S,2S)-2-(1H-imidazol-
4-yl)cyclopropylamine (1b) (VUF 5297) as the eutomer,
having moderate H3 activity. Its enantiomer VUF 5296
is about 10 times less potent. Both stereoisomers show
partial agonistic activity. Minor differences in potencies
between the two functional assays were found. There-
fore, the suggested H3 receptor heterogeneity2 is not
manifested by compounds 1a,b.
During the preparation of this manuscript, Khan et
al.26 reported the synthesis of trans-cyclopropylhista-
mine (1a,b) via a diastereomeric synthesis route analo-
gous to the route developed by Burger et al.13 Surpris-
ingly, they reported (1R,2R)-2-(1H-imidazol-4-yl)cyclo-
propylamine (1a) to be the most active enantiomer.
Unfortunately, no analytical characterization of the
ligands was reported by Khan and co-workers; we were
therefore unable to compare the optical rotation of the
cyclopropylhistamines prepared in the different labo-
ratories. It should be noted that a modeling study by
Sippl et al.27 suggested that (1S,2S)-cyclopropylhista-
mine (1b) provided the best sterical agreement with the
derived H3 receptor pharmacophore model. Our present
study supports these theoretical findings.
The rigid cyclopropylhistamine derivatives show only
a moderate to low H1 and H2 receptor activity. The
histamine H1 receptor has a slight preference for the
(1S,2S)-enantiomer 1b.
Conclusion
A rapid and convenient synthesis and resolution of
trans-2-(1H-imidazol-4-yl)cyclopropylamine (trans-cy-
clopropylhistamine) is described. (1S,2S)-2-(1H-imid-
azol-4-yl)cyclopropylamine (VUF 5297) (1b) is a rigid
H3 receptor agonist about 10 times more active as its
enantiomer. These results have enabled us to construct
an unambiguous pharmacophore model for the hista-
mine H3 receptor, explaining agonistic and antagonistic
activity of histamine H3 ligands, as will be published
elsewhere.28
Experimental Section
Chemistry. 1H and 13C NMR spectra were recorded on a
Bruker AC-200 spectrometer with tetramethylsilane as an
internal standard. Mass spectra were recorded on a Finnigan
MAT-90 spectrometer. Melting points were determined on a
Mettler FP-5 + FP-52 apparatus and are uncorrected. GLC
analysis was performed on a Shimadzu GC-14A instrument
equipped with an FID detector and an HP1 column (50 m 
0.31 mm). Elemental analyses was performed by Micro Kemi
AB, Uppsala, Sweden. Solvents were purified and dried by
standard procedures before use.
Methyl (E)-3-(1H-Imidazol-4-yl)acrylate. Urocanic acid
(25.0 g, 0.18 mol) was added to refluxing methanol (150 mL),
and HCl gas was bubbled through the mixture, according to
literature procedures.29 After refluxing for 5 h, the clear
solution was cooled to 5 °C and white needlelike crystals
appeared (32.20 g, 94.4%). Mp: 233.5-234.5 °C.
Methyl (E)-3-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-
4-yl)acrylate (5). Methyl (E)-3-(1H-imidazol-4-yl)acrylate
(32.20 g, 0.17 mol) was dissolved in a solution of dichlo-
romethane (600 mL) and triethylamine (75 mL). After the
addition of N,N-dimethylsulfamoyl chloride (20.0 mL, 0.19
mol), the reaction mixture was refluxed for 48 h. The solution
was washed with H2O (150 mL) and saturated aqueous sodium
chloride (150 mL). After evaporation of the dichloromethane,
a white solid (43.37 g) remained. Recrystallization from
2-propanol resulted in white crystals (37.55 g, 84.8%). Mp:
137.0-138.0 °C. 1H NMR (CDCl3): ä 2.89 (s, 6H, NCH3), 3.80
(s, 3H, OCH3), 6.67 (d, J ) 15.6 Hz, 1H), 7.38 (s, 1H), 7.52 (d,
J ) 15.6 Hz, 1H), 7.90 (s, 1H). 13C NMR (CDCl3): ä 38.2, 51.7,
118.7, 119.1, 134.4, 137.5, 139.3, 167.3. Anal. (C9H13N3O4S)
C, H, N.
trans-2-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-4-yl)-
cyclopropanecarboxylic Acid. A solution of N-methyl-N-
nitroso-p-toluenesulfonamide (Diazogen) (40.0 g, 0.19 mol)
dissolved in ether (200 mL) was added dropwise to a heated
mixture of KOH (31.0 g, 0.55 mol in 200 mL of H2O) and 2-(2-
ethoxyethoxy)ethanol (200 mL); special ‘soft’ glassware was
used. The hence generated etheric diazomethane solution was
distilled dropwise into a solution of (E)-5 (5.0 g, 19.3 mmol)
and Pd(OAc)2 (200 mg) in dichloromethane (1 L) at room
temperature. The light-yellow solution became dark-brown,
and N2 evolution was observed. The reaction mixture was
stirred overnight. After the addition of a few drops acetic acid,
the reaction mixture was washed with 5% NaHCO3 solution
(250 mL). The organic layer was dried over Na2SO4, filtered
over a short silica column, and concentrated in vacuo. The
remaining light-yellow oil consisted of 49% product 6a,b and
51% starting material (GC and 1H NMR). The residue was
dissolved in dichloromethane (1 L), and the procedure was
repeated, employing the same amounts of reagents. This time
the residual oil consisted of 82% cyclopropane product and 18%
starting material. 1H NMR (CDCl3) 6a,b: ä 1.42-1.57 (m, 2H),
2.03-2.13 (m, 1H), 2.30-2.48 (m, 1H), 2.84 (s, 6H), 3.70 (s,
3H), 7.08 (s, 1H), 7.77 (s, 1H).
The crude product was dissolved in a mixture of methanol
(100 mL) and tetrahydrofuran (100 mL). A portion of 1 M KOH
solution (100 mL) was added, and after 0.5 h of stirring at
room temperature, the mixture was washed with dichlo-
romethane (3  200 mL). The aqueous layer was treated with
1 M HCl solution until the mixture had a pH of 2. The product
was extracted with dichloromethane (3  200 mL), and after
drying over Na2SO4, filtration, and evaporation of the dichlo-
romethane, a light-brown solid (3.91 g) remained. After several
triturations with dry acetone, a white powder (2.92 g, 58.4%)
was collected. Mp: 166.0 °C. 1H NMR (DMSO-d6): ä 1.28-
1.37 (m, 2H), 1.78-1.88 (m, 1H), 2.28-2.38 (m, 1H), 2.78 (s,
6H), 7.50 (s, 1H), 8.00 (s, 1H), 12.28 (bs, 1H). 13C NMR (DMSO-
d6): ä 14.8, 18.7, 22.0, 37.7, 114.1, 136.7, 141.5, 173.8. Anal.
(C9H13N3O4S) C, H, N.
trans-2-(1H-Imidazol-4-yl)cyclopropylamine (1a,b). Ra-
cemic trans-2-(1-(N,N-dimethylsulfamoyl)-1H-imidazol-4-yl)-
cyclopropanecarboxylic acid (2.22 g, 8.6 mmol) was dissolved
in dry acetone (65 mL) and triethylamine (1.6 mL, 11.5 mmol)
under N2 atmosphere. The reaction mixture was cooled to 0
°C, and ethyl chloroformate (1.6 mL, 16.7 mmol) was added
dropwise (a white precipitate formed). After 2 h, a solution of
sodium azide (0.85 g, 13.1 mmol in 15 mL of H2O) was added
slowly, and the mixture was stirred for another hour. After
addition of H2O (65 mL), the solution was concentrated in
vacuo until the water layer remained. The water layer was
extracted with toluene (3  65 mL), and the combined toluene
layers were dried over Na2SO4, filtered, and refluxed for 2 h
(N2 evolution was observed). The residue after evaporation of
toluene was refluxed in tert-butyl alcohol (50 mL) for 12 h
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(disappearance of the isocyanate peak in IR spectrum). After
evaporation of the alcohol a dark residue remained. This
residue was dissolved in ethyl acetate and filtered over a short
silica column. A white solid (2.10 g) remained after evaporation
of the ethyl acetate. This was refluxed for 12 h in 1 M HCl
(100 mL). After concentration in vacuo, the residue was
refluxed in absolute ethanol (60 mL) for 0.5 h, concentrated,
and subsequently washed with acetone. A beige solid (1.06 g,
63%) remained, which was recrystallized from 2-propanol/
ether. Mp: 187.0-187.5 °C. 1H NMR (D2O): ä 1.42 (ddd, J )
6.7, 6.9 and 8.2 Hz, 1H), 1.55 (ddd, J ) 4.7, 7.2 and 10.2 Hz,
1H), 2.51 (ddd, J ) 3.4, 6.5 and 10.1 Hz, 1H), 3.03 (ddd, J )
3.6, 4.5 and 8.2 Hz, 1H), 7.25 (s, 1H), 8.57 (s, 1H). 13C NMR
(D2O): ä 12.4, 12.5, 30.7, 117.4, 132.4, 134.9. Anal. (C6H9N3â
2HCl) C, H, N.
1-(N,N-Dimethylsulfamoyl)-4-iodo-1H-imidazole (8).
N,N-Dimethylsulfamoyl chloride (12.0 mL, 0.11 mol) was
added to a solution of 4-iodo-1H-imidazole (7) (20.0 g, 0.10 mol)
in dichloromethane (600 mL) and triethylamine (40 mL). The
reaction mixture was refluxed for 60 h and subsequently
washed with H2O (250 mL) and 5% Na2S2O3 solution (250 mL).
A light-brown solid (30.22 g) remained after evaporation of the
solvents. Recrystallization from hot 2-propanol resulted in
white crystals (8.65 g, 60%). Mp: 131.5 °C. 1H NMR (CDCl3):
ä 2.89 (s, 6H), 7.34 (s, 1H), 7.78 (s, 1H). 13C NMR (CDCl3): ä
38.2, 84.4, 122.7, 137.8. Anal. (C5H8N3O2SI) C, H, N.
Methyl (1-(N,N-Dimethylsulfamoyl)-1H-imidazol-4-yl)-
propynoate (11). To a solution of 8 (20.0 g, 67 mmol) in
triethylamine (250 mL) was added bis(triphenylphosphine)-
paladium(II) chloride (1 mol %, 0.5 g), CuI (1 mol %, 130 mg),
and trimethylsilylacetylene (20.0 mL, 141 mmol). This reaction
mixture was stirred for 60 h on a 50 °C oil bath. After filtration
of the reaction mixture, the solution was concentrated in vacuo.
1H NMR (CDCl3) 9: ä 0.25 (s, 9H), 2.87 (s, 6H), 7.40 (s, 1H),
7.81 (s, 1H).
The residue 9 was dissolved in methanol (150 mL) and
tetrahydrofuran (150 mL). A solution of 2 M potassium
hydroxide (150 mL) was added, and the mixture was poured
in a saturated NH4Cl solution (150 mL). After extraction of
the product with dichloromethane (1  300 mL, 2  100 mL),
drying over Na2SO4, filtration, and evaporation of the solvent,
a brown oil (12.3 g) remained. The oil was purified by column
chromatography using ethyl acetate as eluent (Rf ) 0.7). A
light-beige solid (1-(N,N-dimethylsulfamoyl)-4-ethynyl-1H-
imidazole) (7.82 g, 59%) was isolated. 1H NMR (CDCl3) 10: ä
2.88 (s, 6H), 3.13 (s, 3H), 7.42 (s, 1H), 7.83 (s, 1H).
This beige solid 10 (5.0 g, 25 mmol) was dissolved in
dichloromethane (50 mL) and added dropwise to a Grignard
mixture, prepared from magnesium (0.8 g, 33 mmol) and ethyl
bromide (2.5 mL, 33 mmol) in tetrahydrofuran (5 mL). After
1 h the mixture was poured in dimethyl carbonate (100 mL)
and stirred overnight. The solution was poured in H2O (250
mL) and extracted with dichloromethane (3  200 mL). After
evaporation of the solvents, a brown oil (5.53 g) remained,
which was purified on a silica gel column with ethyl acetate
as eluent (Rf ) 0.8). After two recrystallizations from 2-pro-
panol, white crystals (2.98 g, 46%) were collected. Mp: 126.0-
127.0 °C. 1H NMR (CDCl3) 11: ä 2.91 (s, 6H, NCH3). 3.84 (s,
3H), 7.63 (s, 1H), 7.88 (s, 1H). 13C NMR (CDCl3) 11: ä 38.2,
52.9, 78.6, 82.1, 123.2, 124.6, 137.1, 154.0. Anal. (C9H11N3O4S)
C, H, N.
Methyl (Z)-3-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-
4-yl)acrylate (5). Compound 11 (2.6 g, 10.1 mmol) was
dissolved in acetone (75 mL). Lindlar catalyst (120 mg) and
quinoline (300 mg) were added, and the reaction mixture was
stirred under hydrogen atmosphere (1 atm). After hydrogen
consumption had ceased, additional Lindlar catalyst was added
(repeated twice; a total of 280 mg of catalyst extra was added).
After 8 h and 300 mL of hydrogen gas consumption, the
reaction mixture was filtered and concentrated in vacuo. The
residue consisted of 92% cis- and 8% trans-isomer, according
to GC. This was purified on a silica gel column with ethyl
acetate as eluent (Rf ) 0.5) and recrystallization from n-
hexane. White crystals (1.8 g, 69%) were isolated. Mp: 74.0
°C. 1H NMR (CDCl3): ä 2.92 (s, 6H), 3.76 (s, 3H), 5.95 (d, J )
12.7 Hz, 1H), 6.96 (d, J ) 12.2 Hz, 1H), 7.88 (s, 1H), 8.64 (s,
1H). Anal. (C9H13N3O4S) C, H, N.
Ethyl trans-2-(4-(Methylphenyl)sulfonyl-4,5-dihydroox-
azol-5-yl)cyclopropanecarboxylate (13a,b). To a stirred
suspension of tosylmethyl isocyanide (6.8 g, 34.6 mmol) and
ethyl trans-2-formyl-1-cyclopropanecarboxylate (12a,b) (5.0 g,
35.2 mmol) in absolute ethanol (250 mL) at 0 °C was added
sodium cyanide (45 mg). For a moment the reaction mixture
became clear followed by precipitation of the product. Ten
minutes after the addition of sodium cyanide, the suspension
was filtered and product was washed with ether/hexane (20
mL, 1/1, v/v) and dried in vacuo. The product was isolated as
a white hygroscopic solid (9.9 g, 85%). Mp: 107.0 °C. 1H NMR
(CDCl3): ä 0.96-1.06 (m, 1H), 1.25 (t, J ) 7.14 Hz, 3H), 1.55-
1.77 (m, 2H), 1.79-1.89 (m, 1H), 2.55 (s, 3H), 4.12 (q, J ) 7.14
Hz, 2H), 4.72 (dd, 1H, J ) 4.11, 4.11 Hz), 4.92 (dd, J ) 4.11,
1.63 Hz, 1H), 6.97 (d, J ) 1.63 Hz, 1H), 7.36 (d, J ) 8.16 Hz,
2H), 7.80 (d, J ) 8.16 Hz, 2H). 13C NMR (CDCl3): ä 12.39,
14.00, 16,77, 21.55, 24.20, 60.84,79.32, 89.72, 129.07, 129.72,
132.69, 145.56, 159.16, 172.37.
Ethyl trans-2-(1H-Imidazol-4-yl)cyclopropanecarbox-
ylate (14a,b). In a stainless steal bomb, a solution of oxazoline
13a,b (9.0 g, 26.7 mmol) and saturated solution of ammonia
in absolute ethanol (120 mL) was heated at 120 °C for 25 h.
The pressure increased to 12 atm. After cooling, the solvent
was removed under reduced pressure. The dark, oily residue
was dissolved in ethyl acetate/dichloromethane (150 mL, 4/1,
v/v) and washed with saturated aqueous sodium chloride (5
 50 mL). The organic layer was dried over sodium sulfate,
filtered, and concentrated in vacuo to give the product as an
oil (3.56 g, 74%). 1H NMR (CDCl3): ä 1.18 (t, J ) 7.14 Hz,
3H), 1.28-1.38 (m, 1H), 1.39-1.48 (m, 1H), 1.82-1.93 (m, 1H),
2.37-2.48 (m, 1H), 4.06 (q, J ) 7.14 Hz, 2H), 6.77 (s, 1H), 7.45
(s, 1H).
Ethyl trans-2-(1-(N,N-Dimethylsulfamoyl)-1H-imida-
zol-4-yl)cyclopropanecarboxylate (15a,b). To a solution of
14a,b (3.00 g, 16.9 mmol) and triethylamine (5.0 mL, 36.1
mmol) in dichloromethane (70 mL) was added N,N-dimethyl-
sulfamoyl chloride (3.1 mL, 28.9 mmol). Subsequently, the
reaction mixture was refluxed for 22 h. Concentration under
reduced pressure followed by flash column chromatography
(ethyl acetate/hexane, 5/3, v/v, Rf ) 0.5) gave the product as a
yellow oil (4.13 g, 85%). 1H NMR (CDCl3): ä 1.26 (t, J ) 6.67
Hz, 3H), 1.37-1.58 (m, 2H), 1.98-2.10 (m, 1H), 2.36-2.48 (m,
1H), 2.87 (s, 6H), 4.14 (q, J ) 6.67 Hz, 2H), 7.04 (s, 1H), 7.72
(s, 1H).
trans-2-(1-(N,N-Dimethylsulfamoyl)-1H-imidazol-4-yl)-
cyclopropanecarboxylic Acid. Compound 15a,b (2.5 g, 8.69
mmol) was dissolved in a mixture of methanol (100 mL) and
THF (100 mL). At room temperature, 1 M KOH solution (100
mL) was added, and after 0.5 h stirring, the mixture was
washed with dichloromethane (3  100 mL). The water layer
was acidified with 1 M HCl until a pH of 2 and extracted with
dichloromethane (3  100 mL). The organic layer was dried
over sodium sulfate, filtered, and concentrated in vacuo to give
a white powder (2.25 g, 75%). Mp: 166.0 °C. 1H NMR (DMSO-
d6): ä 1.28-137 (m, 2H), 1.78-1.88 (m, 1H), 2.28-2.38 (m, 1H),
2.78 (s, 6H), 7.50 (s, 1H), 8.00 (s, 1H), 12.28 (bs, 1H). Anal.
(C9H13N3O4S) C, H, N.
1′(R)-1-(2-Naphthyl)ethyl trans-[2-(1-(N,N-Dimethyl-
sulfamoyl)-1H-imidazol-4-yl)cyclopropyl]carbamate (17,
18). To a solution of racemic trans-2-(1-(N,N-dimethylsulfa-
moyl)-1H-imidazol-4-yl)cyclopropanecarboxylic acid (4.44 g,
17.2 mmol) and triethylamine (3.2 mL, 3.0 mmol) in acetone
(125 mL) at 0 °C was added dropwise ethyl chloroformate (3.2
mL, 33.4 mmol). After 2 h, a solution of sodium azide (1.70 g,
26.2 mmol) in H2O (25 mL) was added slowly to the formed
suspension and stirred for an additional hour. After addition
of water (100 mL), the solution was extracted with toluene (3
 100 mL). The organic layer was dried over sodium sulfate.
After filtration, the solution was refluxed for 2 h (N2 evolution
was observed). Subsequently, (R)-(+)-1-(2-naphthyl)ethanol
(3.26 g, 18.9 mmol) was added. The mixture was refluxed for
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13 h. After evaporation of the solvent, the diastereomeric
carbamates were isolated using a short silica gel column (ethyl
acetate, Rf ) 0.6) to give a white powder (6.41 g, 87%). The
ratio of diastereoisomers was determined using HPLC analysis
as 50:50 (Chrompack CPtm SpherSi, eluent ethyl acetate/
hexane, 60/40, v/v, at 1 mL/min; P ) 20 bar) (11 has a retention
time of 19.68 min, and 12 has a retention time of 23.58 min).
Subsequent separation by flash column chromatography (ethyl
acetate/hexane, 4/1, v/v, Rf ) 0.26) gave the separate diaste-
reoisomers. The diastereomeric purity of the isolated com-
pounds were verified by HPLC.
1′(R)-1-(2-Naphthyl)ethyl (1R,2R)-[2-(1-(N,N-Dimethyl-
sulfamoyl)-1H-imidazol-4-yl)cyclopropyl]carbamate (17).
Rf ) 0.60 (ethyl acetate). Mp: 156.0-157.0 °C. [R]30546 ) +65.0°
(c 0.24, CHCl3). 1H NMR (CDCl3): ä 1.04-1.19 (m, 1H), 1.23-
1.33 (m, 1H), 1.56 (d, J ) 6.58 Hz, 3H), 1.91-2.01 (m, 1H),
2.70 (s, 6H), 2.82-2.98 (m, 1H), 5.53 (bs, 1H), 5.94 (q, J )
6.58 Hz, 1H), 6.97 (s, 1H), 7.44-7.46 (m, 3H), 7.72-7.80 (m,
5H). 13C NMR (CDCl3): ä 14.68, 18.10, 22.27, 31.74, 37.89,
72.77, 112.99, 123.92, 124.66, 125.83, 126.03, 127.48, 127.85,
128.13, 132.78, 132.99, 136.05, 139.28, 142.89, 156.31.
(1′R)-1-(2-Naphthyl)ethyl (1S,2S)-[2-(1-(N,N-Dimethyl-
sulfamoyl)-1H-imidazol-4-yl)cyclopropyl]carbamate (18).
Rf ) 0.57 (ethyl acetate). Mp: 157.0-158.5 °C. [R]30546 ) +5.6°
(c 0.24, CHCl3). 1H NMR (CDCl3): 1.04-1.19 (m, 1H), 1.23-
1.33 (m, 1H), 1.58 (d, J ) 6.58 Hz, 3H), 1.91-2.01 (m, 1H),
2.75 (s, 6H), 2.82-2.98 (m, 1H), 5,30 (bs, 1H), 5.95 (q, J )
6.58 Hz, 1H), 6.99 (s, 1H), 7.44-7.46 (m, 3H), 7.72-7.80 (m,
5H). 13C NMR (CDCl3): ä 14.66, 18.10, 22.40, 31.19, 37.95,
72.88, 76.31, 76.94, 77.58, 112.98, 123.89, 124.65, 125.84,
126.03, 127.48, 127.86, 128.12, 132.78, 133.00, 136.05, 139.22,
142.88, 156.24. Single crystals of this diastereoisomer 18 were
obtained by recrystallization from ethanol.
X-ray crystal data for 18: C21H24N4O4S, Mr ) 428.5,
monoclinic, P21, a ) 13.930(1) Å, b ) 5.4967(4) Å, c ) 15.928-
(1) Å, V ) 1138.7(1) Å3, Z ) 2, Dx ) 1.25 g cm-3, ì(Cu KR) )
1.5418 Å, ì(Cu KR) ) 15.01 cm-1, F(000) ) 452, room
temperature; final R ) 0.096 for 876 observed reflections.
A crystal with approximate dimensions of 0.03  0.05  0.60
mm was used for data collection on an Enraf-Nonius CAD-4
diffractometer with graphite-monochromated Cu KR radiation
and ö-2ı scan. A total of 2403 unique reflections were
measured within the range -16 e h e 15, 0 e k < 6, 0 e l e
19. Of these, 876 were above the significance level of 2.5ó(I).
The range of (sin ı)/ì was 0.034-0.609 Å-1 (3.0 < ı < 69.9°).
Two reference reflections (203, 212) were measured hourly and
showed no decrease during the 57-h collecting time. In
addition, 611 “Friedel” reflections were measured, which were
used in the determination of the absolute configuration. Unit-
cell parameters were refined by least-squares fitting procedure
using 23 reflections with 68 < 2ı < 78°. Corrections for Lorentz
and polarization effects were applied. The structure was solved
by the PATTY option of the DIRDIF94 program system.30 The
hydrogen atoms restraining the latter in such way that the
distance to their carrier remained constant at approximately
1.0 Å and keeping their displacement factors fixed at U ) 0.1
Å, converged to R ) 0.096, Rw ) 0.123, (¢/ó)max ) 0.09, S )
1.07. A weighting scheme, w ) [10.0 + 0.01*(ó(Fobs))2 + 0.0001/
(ó(Fobs))]-1, was used. The secondary isotropic extinction coef-
ficient31,32 refined to Ext ) 0.08(3). The absolute structure
parameter33 refined to Xabs ) -0.04(20), thus confirming the
correct enantiomer. A final difference Fourier map revealed a
residual electron density between -0.7 and 1.3 e Å-3 in the
vicinity of the S atom. Scattering factors were taken from
Cromer and Mann34 International Tables for X-ray Crystal-
lography (1974). The anomalous scattering of S was taken into
account. All calculations were performed with XTAL3.4,35
unless stated otherwise.
(1R,2R)-2-(1H-Imidazol-4-yl)cyclopropylamine (VUF
5296) (1a). A solution of 17 (1.25 g, 2.92 mmol) in 30% HBr
(75 mL) was refluxed for 22 h. After concentration in vacuo,
the residue was refluxed in absolute ethanol for 0.5 h and
subsequently washed with acetone. White crystals (0.64 g,
77%) were collected. Mp: 207.0-208.0 °C. [R]30546 ) +54.4° (c
0.35, H2O). 1H NMR (D2O): ä 1.42 (ddd, J ) 6.7, 6.9, and 8.2
Hz, 1H), 1.55 (ddd, J ) 4.7, 7.2, and 10.2 Hz, 1H), 2.51 (ddd,
J ) 3.4, 6.5, and 10.1 Hz, 1H), 3.03 (ddd, J ) 3.6, 4.5, and 8.2
Hz, 1H), 7.25 (s, 1H), 8.57 (s, 1H). Anal. (C6H11N3Br2) C, H,
N.
(1S,2S)-2-(1H-Imidazol-4-yl)cyclopropylamine (VUF
5296) (1b). A solution of 18 (1.00 g, 2.33 mmol) in 30% HBr
(75 mL) was refluxed for 22 h. After concentration in vacuo,
the residue was refluxed in absolute ethanol for 0.5 h and
subsequently washed with acetone. White crystals (0.51 g,
76%) were collected. Mp: 207.0-208.0 °C. [R]30546 ) -54.2° (c
0.35, H2O). 1H NMR (D2O): ä 1.42 (ddd, J ) 6.7, 6.9, and 8.2
Hz, 1H), 1.55 (ddd, J ) 4.7, 7.2, and 10.2 Hz, 1H), 2.51 (ddd,
J ) 3.4, 6.5, and 10.1 Hz, 1H), 3.03 (ddd, J ) 3.6, 4.5, and 8.2
Hz, 1H), 7.25 (s, 1H), 8.57 (s, 1H). Anal. (C6H11N3Br2) C, H,
N.
Pharmacology. The compounds were tested for their
activity on the histamine receptors in different assays (vide
supra). These assays were previously described in detail.22-25
The histamine H3 receptor affinity was determined in rat
cortical membranes with [3H]-NR-methylhistamine (81.9 Ci/
mmol; NEN Life Science Products, Brussels, Belgium) accord-
ing to the method of West et al.36 with modifications. Briefly
animals were killed by decapitation, and the cerebral cortex
was rapidly removed. Rat cortices were homogenized in 15
volumes (wt/vol) of ice-cold Tris/HCl buffer (50 mM Tris/HCl,
5 mM MgCl2, 145 mM NaCl, pH 7.4 at 4 °C) using an Ultra-
Turrax homogenizer (8 s) and a glass-Teflon homogenizer
(four strokes up and down) subsequently. All subsequent steps
were carried out at 0-4 °C. The homogenate was centrifuged
at 800g for 10 min. The pellets were discarded, and the
supernatant was centrifuged for 20 min at 40000g. The
resulting pellet was resuspended, and the last centrifugation
step was repeated. The pellet was resuspended in 1.5 volumes
(wt/vol) of Tris/HCl buffer to give a final concentration of 300
íg/100 íL and stored in aliquots at -80 °C. Protein concentra-
tion was determined using Biorad protein assay (Bio-Rad
Laboratories GmbH, Munich, Germany). Competition binding
experiments were carried out in polypropylene tubes in a total
volume of 400 íL of 50 mM Na+ phosphate buffer, pH 7.4 at
37 °C, containing 30 íg of protein, 1 nM [3H]-NR-methylhis-
tamine, and 0.1-10 000 nM compound to be tested. Samples
were incubated for 40 min at 25 °C. The incubation was started
by the addition of 100 íL of membranes (30 íg) and terminated
by rapid filtration through poly(ethylenimine) (0.3 wt %/vol)
pretreated Whatman GF/C filters using a Brandel filtration
apparatus. The filters were washed twice with 3 mL of ice-
cold Tris/HCl buffer (50 mM Tris/HCl, 5 mM MgCl2, 145 mM
NaCl, pH 7.4 at 4 °C). The radioactivity retained on the filters
was measured using liquid scintillation counting. Competition
isotherms were analyzed with the GraphPad Prism software
(GraphPad, Intuitive Software for Science, San Diego, CA).
Ki values were determined with the equation Ki ) IC50/(1 +
([ligand]/Kd)).
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